Design, Synthesis and Preliminary Antimicrobial Evaluation of N-Alkyl Chain Tethered C-5 Functionalized Bis-Isatins.

A series of N-alkyl tethered C-5 functionalized bis-isatins were synthesized and evaluated for antimicrobial activity against pathogenic microorganisms. The preliminary evaluation studies revealed the compound 4t, with an optimal combination of bromo-substituent at the C-5 position of isatin ring along with propyl chain linker being most active among the synthesized series exhibiting an IC50 value of 3.72 μM against Trichomonas vaginalis while 4j exhibited an IC50 value of 14.8 μM against Naegleria fowleri, more effective than the standard drug Miltefosine. The compound 3f with an octyl spacer length was the most potent among the series against Giardia lamblia with an IC50 of 18.4 μM while 3d exhibited an IC50 of 23 μM against Entamoeba histolytica. This library was also screened against the fungal pathogen Aspergillus parasiticus. A number of the compounds demonstrated potency against this fungus, illustrating a possible broad-spectrum activity. Furthermore, an evaluation of these synthesized compounds against a panel of normal flora bacteria revealed them to be non-cytotoxic, demonstrating the selectivity of these compounds. This observation, in combination with previous studies that isatin is non-toxic to humans, presents a new possible scaffold for drug discovery against these important protozoal pathogens of humans and animals.

[1]  Vipan Kumar,et al.  4-Aminoquinoline-chalcone/-N-acetylpyrazoline conjugates: Synthesis and antiplasmodial evaluation. , 2017, European journal of medicinal chemistry.

[2]  Vipan Kumar,et al.  Piperazine‐linked 4‐aminoquinoline‐chalcone/ferrocenyl‐chalcone conjugates: Synthesis and antiplasmodial evaluation , 2017, Chemical biology & drug design.

[3]  Vipan Kumar,et al.  4-Aminoquinoline-ferrocenyl-chalcone conjugates: Synthesis and anti-plasmodial evaluation. , 2017, European journal of medicinal chemistry.

[4]  L. Eckmann,et al.  Nitroimidazole carboxamides as antiparasitic agents targeting Giardia lamblia, Entamoeba histolytica and Trichomonas vaginalis , 2016, European journal of medicinal chemistry.

[5]  H. Abdel‐Aziz,et al.  Bis-isatin hydrazones with novel linkers: Synthesis and biological evaluation as cytotoxic agents. , 2016, European journal of medicinal chemistry.

[6]  Vipan Kumar,et al.  Synthesis and antiprotozoal activity of mono- and bis-uracil isatin conjugates against the human pathogen Trichomonas vaginalis. , 2015, Bioorganic & medicinal chemistry.

[7]  Sun Park,et al.  Novel cathepsin B and cathepsin B-like cysteine protease of Naegleria fowleri excretory–secretory proteins and their biochemical properties , 2014, Parasitology Research.

[8]  Nisha,et al.  Cu(I)Cl-promoted synthesis of novel N-alkylated isatin analogs with an extension toward isatin-4-aminoquinoline conjugates: in vitro analysis against Trichomonas vaginalis , 2014, Medicinal Chemistry Research.

[9]  J. Gut,et al.  Hsp90 Inhibitors as New Leads To Target Parasitic Diarrheal Diseases , 2014, Antimicrobial Agents and Chemotherapy.

[10]  Vipan Kumar,et al.  7‐Chloroquinoline–isatin Conjugates: Antimalarial, Antitubercular, and Cytotoxic Evaluation , 2014, Chemical biology & drug design.

[11]  Nisha,et al.  N-Propargylated isatin-Mannich mono- and bis-adducts: Synthesis and preliminary analysis of in vitro activity against Tritrichomonas foetus , 2014, European Journal of Medicinal Chemistry.

[12]  Nisha,et al.  Design and synthesis of β-amino alcohol based β-lactam–isatin chimeras and preliminary analysis of in vitro activity against the protozoal pathogen Trichomonas vaginalis , 2013 .

[13]  Vipan Kumar,et al.  Synthesis of 1H-1,2,3-triazole linked β-lactam-isatin bi-functional hybrids and preliminary analysis of in vitro activity against the protozoal parasite Trichomonas vaginalis. , 2013, European journal of medicinal chemistry.

[14]  S. Hales,et al.  Potential effects of global environmental changes on cryptosporidiosis and giardiasis transmission. , 2013, Trends in parasitology.

[15]  J. McKerrow,et al.  Corifungin, a New Drug Lead against Naegleria, Identified from a High-Throughput Screen , 2012, Antimicrobial Agents and Chemotherapy.

[16]  M. Arendrup,et al.  EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[17]  M. Arkin,et al.  A high throughput drug screen for Entamoeba histolytica identifies a new lead and target , 2012, Nature Medicine.

[18]  C.-C. Shu,et al.  Mycobacterial peritonitis: difference between non-tuberculous mycobacteria and Mycobacterium tuberculosis. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[19]  S. West,et al.  Mechanisms of Pathogenesis, Infective Dose and Virulence in Human Parasites , 2012, PLoS pathogens.

[20]  Vipan Kumar,et al.  Synthesis and in vitro cytotoxic evaluation of N-alkylbromo and N-alkylphthalimido-isatins. , 2011, Bioorganic & medicinal chemistry letters.

[21]  P. Upcroft,et al.  Hydrogenosomes of Laboratory‐Induced Metronidazole‐Resistant Trichomonas vaginalis Lines are Downsized While Those from Clinically Metronidazole‐Resistant Isolates Are Not , 2010, The Journal of eukaryotic microbiology.

[22]  R. Fichorova Impact of T. vaginalis infection on innate immune responses and reproductive outcome. , 2009, Journal of reproductive immunology.

[23]  F. Hilberg,et al.  Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). , 2009, Journal of medicinal chemistry.

[24]  Maureen Miller,et al.  Factors associated with the prevalence and incidence of Trichomonas vaginalis infection among African American women in New York city who use drugs. , 2008, The Journal of infectious diseases.

[25]  R. Roskoski,et al.  Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. , 2007, Biochemical and biophysical research communications.

[26]  J. Baeten,et al.  Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. , 2007, The Journal of infectious diseases.

[27]  P. Marynen,et al.  Efficacy of the Kinase Inhibitor SU11248 against Gastrointestinal Stromal Tumor Mutants Refractory to Imatinib Mesylate , 2006, Clinical Cancer Research.

[28]  W. Secor,et al.  Trichomonas vaginalis-Induced Epithelial Monolayer Disruption and Human Immunodeficiency Virus Type 1 (HIV-1) Replication: Implications for the Sexual Transmission of HIV-1 , 2005, Infection and Immunity.

[29]  Hans Briem,et al.  From the Insoluble Dye Indirubin towards Highly Active, Soluble CDK2‐Inhibitors , 2005, Chembiochem : a European journal of chemical biology.

[30]  B. Yoon,et al.  Metronidazole-induced encephalopathy , 2004, Journal of the Neurological Sciences.

[31]  I. M. El-Ashmawy,et al.  Reproductive and cytogenetic toxicity of metronidazole in male mice. , 2004, Basic & clinical pharmacology & toxicology.

[32]  P. Greengard,et al.  Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. , 2004, Journal of medicinal chemistry.

[33]  P. Moodley,et al.  Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  P. Upcroft,et al.  Drug Targets and Mechanisms of Resistance in the Anaerobic Protozoa , 2001, Clinical Microbiology Reviews.

[35]  P. Upcroft,et al.  Efficacy of New 5-Nitroimidazoles against Metronidazole-Susceptible and -Resistant Giardia,Trichomonas, and Entamoeba spp , 1999, Antimicrobial Agents and Chemotherapy.

[36]  T. Quinn,et al.  Diagnosis of Trichomonas vaginalisInfection by PCR Using Vaginal Swab Samples , 1998, Journal of Clinical Microbiology.

[37]  Z. F. Zhang,et al.  Trichomonas vaginalis and cervical cancer. A prospective study in China. , 1995, Annals of epidemiology.

[38]  J. Krieger Trichomoniasis in Men: Old Issues and New Data , 1995, Sexually transmitted diseases.

[39]  J. Walsh,et al.  Problems in recognition and diagnosis of amebiasis: estimation of the global magnitude of morbidity and mortality. , 1986, Reviews of infectious diseases.

[40]  M. Kidwai Isatins: A Diversity Orientated Biological Profile , 2014 .

[41]  R. Figlin,et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  D. Soper Trichomoniasis: under control or undercontrolled? , 2004, American journal of obstetrics and gynecology.

[43]  P. Piot,et al.  Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. , 1993 .

[44]  D. Keister Axenic culture of Giardia lamblia in TYI-S-33 medium supplemented with bile. , 1983, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[45]  L S Diamond,et al.  A new medium for the axenic cultivation of Entamoeba histolytica and other Entamoeba. , 1978, Transactions of the Royal Society of Tropical Medicine and Hygiene.